Navigation Links
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
Date:11/3/2008

eated with various chemotherapies.

The study showed that AEZS-108 was well tolerated by patients with gynaecological tumors. Furthermore, AEZS-108 is the first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to LHRH-receptor expressing tumors. Finally, signs of anti-tumor activity were observed in 7 out of 13 patients treated with 160 or 267 mg/m2 of AEZS-108, including three patients with complete or partial response.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors, results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic drug, doxorubicin, in the cells. Therefore, since they target specific cells, cytotoxic conjugates are postulated to be less toxic, have less side-effects and are more effective in vivo than the respective non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.

About endometrial and Ovarian Cancer

Cancer of the endometrium is the most common gynaecologic malignancy and accounts for 6% of all cancers in women. The majority of the cases occur in postmenopausal women, with the largest number of women developing their cancers during the sixth decade. Approximately 38,000 new cases and 9,000 deaths from this disease are estimated annually in Europe (Source: Annals of Oncology 15:1149-1150, 2004).

Ovarian cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovari
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 2014 The report “Service ... Market by Product Type & Provider Type ... (2014-2019)” defines and segments the market with ... , Browse 152 market data tables, ... in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014 ... ) announced today that Medtronic, Inc. (NYSE: ... application to the U.S. Food and Drug Administration ... II implantable drug infusion system (including a ... Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... a biopharmaceutical company advancing patient care in critical areas, ... 3,500,000 shares of common stock, and warrants to purchase ... at an offering price of $4.00 per share and ... exercise price of $5.00, are exercisable immediately, and expire ...
(Date:12/24/2014)... 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ... Under the terms of the private ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Oct. 27 Precision Antibody(TM) has been ... the National Cancer Institute (NCI),s Clinical Proteomic Technologies for ... and standardizing the quality of monoclonal antibody reagents available ... the result of a third solicitation for contract proposals ...
... ... These products will not only provide antimicrobial protection, they are low in VOC,s (volatile ... additive chemistry is available in a wide range of RB Rubber products. , ... McMinnville, OR (PRWEB) October ...
... , NEW YORK, Oct. 26 ... research report is available in its ... Bioinformatics and Computational Biology: Bottlenecks and ... http://www.reportlinker.com/p0156561/Reportlinker-Adds-Bioinformatics-and-Computational-Biology-Bottlenecks-and-Options.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , The interdisciplinary ...
Cached Biology Technology:Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products 2RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products 3Reportlinker Adds Bioinformatics and Computational Biology: Bottlenecks and Options 2Reportlinker Adds Bioinformatics and Computational Biology: Bottlenecks and Options 3
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its ... has helped thousands of people to eliminate the pain ... replacing the antiquated system with their own biometrics fused ... to remember usernames and passwords, Hoyos Labs , ... identity, announced today that it is offering the app ...
(Date:12/22/2014)... 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... consultant, Apollo Robbins for the 2015 International ... Apollo Robbins will be at ... 2015, demonstrating some of his famous theft techniques to ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... 2012 Cardium Therapeutics (NYSE Amex: CXM) today announced ... Gene & Cell Therapy (ASGCT) 15th Annual Meeting being ... in Philadelphia, PA. The new ... role in adenovector gene transfection (delivery) in mammalian hearts. ...
... a sort of giant living organism as the Gaia hypothesis ... may provide a key to answering this question. This key ... between ocean organisms, atmosphere, and land -- interactions that might ... -- first articulated by James Lovelock and Lynn Margulis in ...
... changes in air pollution were associated with changes in biomarkers ... well as measures of cardiovascular physiology in healthy young persons, ... JAMA, a theme issue on Global Health. ... (CVD), but the mechanisms by which air pollution leads to ...
Cached Biology News:Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial 2UMD finding may hold key to Gaia hypothesis 2UMD finding may hold key to Gaia hypothesis 3Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 2Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 3Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 4
... Polymerase is ideal for high-fidelity amplification ... such as cloning and mutagenesis. ... proprietary enzyme preparation containing recombinant DNA ... (3'Cut Site5' exonuclease) activity. Platinum ...
... PLAU N-term Antibody This antibody is generated ... synthetic peptide selected within aa 50~150 of ... in PBS with 0.09% (W/V) sodium azide. ... G column and eluted out with both ...
...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Biology Products: